11. BioMerieux (EPA:BIM): +57.9%
Marcy-l’Étoile, France–based BioMerieux touts itself as a worldwide leader in in-vitro diagnostics, offering microbiological testing solutions for medical and industrial applications. Its R&D spend represented 12.9% of its overall revenue in its most recent fiscal, one of the largest percentages among medtech companies.
“I am determined to continue our family’s commitment to make bioMérieux a flagship company in the field of clinical and industrial diagnostics,” Mérieux said at the time. “Each day we see evidence of the importance of our work, and its impact on patients and consumers.”